Will mRNA-4157 go to phase 3 by 2025?
12
150Ṁ1139resolved Dec 15
Resolved
YES1H
6H
1D
1W
1M
ALL
mRNA-4157 is a personalized cancer vaccine therapy. Short version of how it works: patient gets cancer -> cancer is sequenced -> vaccine is designed to target that sequence -> patient is injected with the mRNA vaccine.
This is the phase 2 trial: https://clinicaltrials.gov/ct2/show/NCT03897881
Resolves yes if a phase 3 trial starts, not just if it passes.
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ232 | |
| 2 | Ṁ21 | |
| 3 | Ṁ1 |
People are also trading
Related questions
Will an H5N1 mRNA vaccine be developed and enter "late stage" human trials (or wider release) by July 2025?
3% chance
Will a drug designed with significant contribution from an AlphaFold-like system pass a Phase I trial by end of 2025?
19% chance
Will an mRNA HIV vaccine pass Phase 2 trials by 2025
21% chance
Will AOH1996 advance past Phase II trials by the end of 2027?
43% chance
Will an AI-designed drug get FDA approval by the end of 2025?
19% chance
Will FDA approve more than 10 new mRNA based vaccines before 2030?
67% chance
Will FDA approve any mRNA vaccine against prostate adenocarcinoma before 2028?
41% chance
Will FDA approve any mRNA vaccine against esophageal adenocarcinoma before 2028?
33% chance
Will FDA approve more than 10 new mRNA based vaccines before 2028?
60% chance
Will FDA approve any type of personalized cancer mRNA vaccines before 2028?
77% chance